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Abstract 
Typhoid fever, infection with Salmonella enterica serovar Typhi (S. Typhi), remains a 
serious health concern in many parts of the world, particularly where sanitation is 
poor. While vaccines against S. Typhi are available, coverage in endemic regions is 
low, leaving antimicrobial therapy central to disease control. Unfortunately, drug 
resistant S. Typhi emerged in the mid-1970s and multi-drug resistance (MDR) is now 
a significant problem in many typhoid endemic areas. In the S. Typhi population, 
MDR is almost exclusively conferred by self-transmissible IncHI1 plasmids carrying 
a suite of antimicrobial resistance genes. We compared eight IncHI1 plasmid 
sequences and identified single nucleotide polymorphisms (SNPs) in the plasmid 
backbone. These were combined with known S. Typhi chromosomal SNPs to 
simultaneously genotype IncHI1 plasmids and their S. Typhi hosts among a collection 
of 454 S. Typhi dating back to 1958. Among isolates collected prior to 1995, a variety 
of IncHI1 plasmid types were observed, present in distinct S. Typhi hosts. Some 
plasmids were detected among distinct S. Typhi lineages co-circulating in time and 
space, indicating the spread of MDR via transfer of plasmids among S. Typhi strains. 
From 1995 onwards, 98% of MDR S. Typhi tested were of the same plasmid-strain 
combination (IncHI1 plasmid sequence type 6 (PST6) and S. Typhi haplotype H58) 
suggesting that the recent global spread of MDR typhoid is the result of clonal 
expansion of a single host-plasmid combination. In competition assays, the ability of 
PST6-bearing S. Typhi to outcompete S. Typhi bearing a distinct IncHI1 plasmid 
(PST1) varied depending on the host strain, suggesting plasmid-strain interactions 
may contribute to the recent success of the PST6 plasmid. Comparison of PST6 and 
PST1 in a common S. Typhi strain background revealed that PST6 conferred 
osmotolerance, which we demonstrate is due to the presence of the Tn6062 
transposon incorporating betU.
Format t ed:  Font :  I t al i c
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Introduction 
Typhoid fever remains a serious public health problem in many developing countries, 
with highest incidence in Asia (274 per 100,000 person-years) and Africa (50 per 
100,000 person-years) (1). Worldwide, the annual typhoid fever burden is estimated 
at more than 20 million cases and half a million deaths (2). The causative agent of 
typhoid fever is the bacterium Salmonella enterica serovar Typhi (S. Typhi). While 
vaccines against S. Typhi exist, it is mainly travellers (3, 4) and people enrolled in 
large vaccine trials (5) who are immunized, and antimicrobial treatment remains 
central to the control of typhoid fever (3). However antimicrobial resistant typhoid 
has been observed for over half a century and is common in many areas. 
Chloramphenicol resistant S. Typhi was first reported in 1950, shortly after the drug 
was introduced for treatment of typhoid (6). By the early 1970s, S. Typhi resistant to 
both chloramphenicol and ampicillin had been observed (7), and multidrug resistant 
(MDR) S. Typhi (defined as resistant to chloramphenicol, ampicillin and 
trimethoprim -sulfamethoxazole) emerged soon after (8). In response, the 
recommended treatment for typhoid was changed in the mid 1990s to the 
fluoroquinolones (3, 9). However susceptibility to these drugs has been declining 
among S. Typhi ever since (10). The rate of MDR among S. Typhi isolated from 
patients fluctuates over time and geographical space, as does the precise combination 
of drug resistance genes and phenotypes (10, 11). However in many typhoid endemic 
areas, an increase in MDR S. Typhi was observed in the late 1990s (12-14). MDR 
typhoid remains a significant problem in many areas (10, 15), including Asia (e.g. 
>50% of cases in Cambodia in 2006-2009 (16) and Mekong Delta, Vietnam in 2004-
2005 (17)), parts of Africa  (e.g. 70% of cases in Nairobi, Kenya in 2004-2006 (18)) 
and the Middle East (e.g. 50% of cases in Jordan in 2004-2005 (19)). MDR is also 
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common among travellers returning to the UK, US or Canada with typhoid fever (20-
22). MDR S. Typhi with reduced susceptibility to fluoroquinolones are now 
frequently observed (10, 16, 17, 23), leaving macrolide (azithromycin) or third 
generation cephalosporins as the only effective therapy (24, 25). 
 
MDR among S. Typhi is almost exclusively conferred by self-transmissible plasmids 
of the HI1 incompatibility type (IncHI1) (8, 12, 26-31), although other plasmids are 
occasionally reported (32). In the laboratory, IncHI1 plasmids can transfer between 
Enterobacteriacae and other Ggram-negative bacteria (33) and in nature, IncHI1 
plasmids have been detected in enteric pathogenic strains of Salmonella and E. coli 
(34-37). 
 
The question of whether the spread of MDR pathogens is due to spread of resistance 
genes/plasmids among circulating pathogens, or to the expansion of MDR pathogen 
clones, is of public health interest. The latter implies that MDR cases are linked 
epidemiologically and the increase in MDR cases could potentially be halted by 
interrupting introduction or transmission of the MDR clone(s). The former suggests 
that MDR is acquired frequently, implying strong selective pressure for the MDR 
phenotype. For example, it was recently demonstrated that the detection of 
methicillin-resistant Staphylococcus aureus (MRSA) ST5 around the world was due 
to frequent acquisition of the methicillin-resistance island by local ST5 strains, rather 
than to global spread of a single MRSA ST5 strain (38). This is informative in that it 
suggests that local patterns of antimicrobial use and infection control, rather than 
international transmission routes, should be the focus of interventions to reduce 
MRSA rates. In contrast, a study of Neisseria gonorrhoeae in Israel found that 
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quinolone resistant cases were the result of occasional imports of resistant strains into 
the local community rather than acquisition of resistance by endemic strains (39). The 
MRSA ST5 study used SNP typing to differentiate among the MRSA population at 
high resolution (38). In S. Typhi, efforts have been made to investigate variability 
among IncHI1 plasmids (30, 34, 40) or among S. Typhi host strains (23, 41-45), but 
little progress has been made in linking the two together to answer fundamental 
questions of how MDR typhoid spreads. Several lines of evidence indicate that MDR 
IncHI1 plasmids have transferred into wildtype S. Typhi populations on multiple 
occasions. Plasmid-associated antimicrobial resistance phenotypes and resistance 
gene content vary among S. Typhi isolates, as do RFLP profiles of IncHI1 plasmids 
found in S. Typhi (30). We recently developed a multi-locus sequence typing (MLST) 
scheme for IncHI1 plasmid sequences, which identified eight distinct IncHI1 plasmid 
sequence types (PSTs) among plasmids from S. Typhi and S. Paratyphi A isolates 
(40), including five PSTs found in S. Typhi (40). Phylogenetic analysis of the 
sequenced loci divided the PSTs into two distinct lineages, both of which were found 
in S. Typhi (40). This pattern is not consistent with a single acquisition of IncHI1 
plasmid in S. Typhi followed by evolution into multiple plasmid lineages, rather it 
indicates that IncHI1 plasmids have entered the S. Typhi population on at least two 
independent occasions. However the phylogenetic relatedness of the host S. Typhi 
strains was not determined, thus we were unable to estimate how many acquisitions 
may have occurred.  
 
In this study, we began with a comparative analysis of all available IncHI1 plasmid 
sequences (N=8) and inferred the timing of independent insertions of drug resistance-
related transposons in IncHI1 plasmids. We then incorporated the SNPs identified in 
p6/52 
this analysis into a high-throughput SNP typing assay, to simultaneously interrogate 
both IncHI1 plasmid and S. Typhi chromosomal sequences in a global collection of 
over 450 S. Typhi isolated during the last 50 years. Using this data, we investigated 
the historical acquisitions of IncHI1 in natural S. Typhi populations. Finally we 
investigated the role of the specific plasmid in this clonal expansion, using a 
combination of phenotype arrays, sequence comparison and gene constructs.
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Results 
Evolution of MDR IncHI1 Plasmids  
We compared the sequences of eight ~200 kbp IncHI1 plasmids (Table 1). The 
plasmids shared a conserved IncHI1 backbone (>99% identical at the nucleotide 
level), including the tra1 and tra2 regions encoding conjugal transfer, as detected in 
previous analyses of 2-3 IncHI1 sequences (30, 34, 40, 46). We identified 347 single 
nucleotide polymorphisms (SNPs) within this conserved backbone, which were used 
to construct a phylogenetic tree (Figure 1). We used a Bayesian inference method 
(implemented in BEAST (47)), which also estimates the divergence dates of internal 
nodes of the tree based on the known isolation dates for the plasmid sequences (48) 
(Figure 1). The tree topology is in agreement with that inferred previously using the 
plasmid MLST approach (40). The three recent S. Typhi sequences (isolated 2003-
2004) were very closely related and correspond to the previously defined plasmid 
sequence type (PST) 6 (40) (Figure 1, red). According to our divergence date 
estimates, the most recent common ancestor (mrca) shared by these three plasmids 
existed circa 1999 (Figure 1). The PST6 plasmids were also closely related to the 
PST7 plasmid pAKU_1 (Figure 1, orange), with mrca circa 1992. The plasmids 
pHCM1, pO111_1 and pMAK1 formed a distinct group corresponding to PST1, with 
mrca circa 1989 (Figure 1, green). The eighth plasmid, R27 (PST5), was quite distinct 
from the others, with an estimated divergence date of 1952 (Figure 1, black). 
 
In addition to the conserved IncHI1 backbone, the plasmids each harbour insertions of 
drug resistance elements. These include transposons Tn10 (encoding tetracycline 
resistance), Tn9 (encoding chloramphenicol resistance via the cat gene), strAB 
(encoding streptomycin resistance), sul1 and sul2 (encoding sulfonamide resistance), 
Format t ed:  Font :  I t al i c
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dfrA7 (encoding trimethoprim resistance) and blaTEM-1 (encoding ampicillin 
resistance), as described previously (30, 34, 49). The insertion sites of these elements, 
determined from sequence data and confirmed via PCR (Tables 2 & 3), differed 
between lineages of the IncHI1 tree (Figure 1). The insertion sites were conserved 
within lineages, enabling us to infer the branch on which each insertion occurred 
(Figure 1, grey). All plasmid sequences included Tn10, however three different 
insertion sites were evident (Table 2), indicating the transposon was acquired by 
IncHI1 plasmids on at least three separate occasions (Figure 1, grey). Tn9 was present 
in all plasmids besides except for R27, however the insertion site in PST6 and PST7 
plasmids differed from that in PST1, indicating at least two independent acquisitions. 
It was previously noted that pHCM1 (PST1) and pAKU_1 (PST7) share identical 
insertions into Tn9 of a sequence incorporating Tn21 (including sul1, dfrA7), blaTEM-
1, sul2, and strAB (34); here we found this insertion into Tn9 was conserved in all 
PST1 and PST6 plasmid sequences. Together, this composite set of drug resistance 
elements encodes resistance to chloramphenicol, trimethoprim-sulfamethoxazole and 
ampicillin (the definition of MDR). These results provide strong evidence that MDR 
IncHI1 PST1 plasmids have spread the MDR phenotype among enteric pathogens 
including S. Choleraesuis (pMAK1), enterohaemorrhagic E. coli O111:H- (pO111_1) 
and some S. Typhi populations (pHCM1). Similarly, MDR IncHI1 PST6 and PST7 
plasmids have spread the MDR phenotype among other S. Typhi populations and S. 
Paratyphi A.  
 
Dissecting the Spread of MDR Typhoid 
In order to investigate the role of IncHI1 plasmids in the historical and current spread 
of MDR S. Typhi, we performed high resolution genotyping of S. Typhi chromosomal 
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and IncHI1 plasmid loci in a global collection of 454 S. Typhi, isolated in 1958-2007 
(Table 4, Table S1). These isolates include as controls 19 S. Typhi isolates sequenced 
previously (50). We also genotyped eight E. coli transconjugants harbouring IncHI1 
plasmids of known plasmid sequence types previously described (30, 40) as 
additional PST controls. In order to increase our coverage of recent African isolates, 
the data presented here includes results from genotyping 22 S. Typhi isolated from 
Kenya in 2004-2007, which we reported previously (23). Genotyping was performed 
using two GoldenGate assays to simultaneously assay chromosomal and plasmid SNP 
loci. We targeted 230 loci in the conserved backbone of the IncHI1 plasmid 
(identified above, Table S2), 6 additional IncHI1 loci previously identified by plasmid 
MLST (40) and 119 loci associated with resistance genes and associated transposons 
(identified among the IncHI1 sequences analysed above) (17). 
 
Of the 454 genotyped S. Typhi, 193 (43%) contained IncHI1 plasmids. These 193 
IncHI1 plasmids clustered into nine distinct haplotypes, their phylogenetic 
relationships are shown in Figure 2b. The majority of IncHI1 plasmids gave positive 
signals for multiple resistance genes or elements including Tn10, Tn9, strAB, sul1, 
sul2, dfrA7 and blaTEM-1. Transposon insertion sites were confirmed for representative 
plasmids using PCR (Table 2) and conform with patterns of insertion sites determined 
from sequence data (Figures 1 & 2b). Only thirteen IncHI1 plasmids were identified 
in S. Typhi isolated prior to 1994 (Table 5), however these few plasmids include 
representatives of seven of the nine IncHI1 plasmid haplotypes.  
 
The phylogenetic distribution of S. Typhi chromosomal haplotypes, which included 
26 distinct clusters, is shown in Figure 2a. PST2 was found in three S. Typhi 
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haplotypes isolated in Asia between 1972 and 1977 (Table 5), consistent with 
repeated introduction of the same or very closely related IncHI1 plasmids into distinct 
S. Typhi lineages. PST8 was present in three S. Typhi isolated from Peru in 1981 (51). 
Two of these host strains were identical at all chromosomal loci assayed (H77) while 
the third host strain had a distinct haplotype (H50, which differed from H77 at 28 
chromosomal SNP loci). It has previously been noted that these strains, and others 
collected contemporaneously at the same location, displayed distinct phage types 
(51). This is consistent with spread of the PST8 plasmid among multiple S. Typhi 
lineages co-circulating in Peru in the early 1980s. After 1994, nearly all IncHI1 
plasmids were PST6 (180/184 plasmids, 98%). (Two PST2 plasmids and a novel 
subtype of PST1, 57Laos, were also detected after 1994; see Figure 2b, Table 3.) 
Remarkably, all of the 180 S. Typhi isolates carrying the PST6 plasmid were of the 
same chromosomal haplotype, H58. This strongly suggests that the apparent spread of 
MDR typhoid since the mid-1990s (12-14) is due to the clonal expansion of H58 S. 
Typhi carrying the MDR PST6 plasmid. This is in contrast to the historical data 
outlined above, in which closely related MDR plasmids appeared to spread among 
distinct co-circulating S. Typhi strains. The earliest S. Typhi H58 present in our 
collection was isolated in 1995 and carried the PST6 plasmid. Of the 390 S. Typhi 
isolated after 1994, 70% were of the H58 haplotype and 65% of these carried the 
PST6 plasmid (we found no S. Typhi H58 isolates carrying other IncHI1 plasmid 
types).  
 
The clonal expansion of H58 S. Typhi has been documented previously (23, 44), 
however the role of the PST6 plasmid has not been investigated. To ascertain whether 
the common ancestor of S. Typhi H58 might have carried the PST6 plasmid, we 
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“zoomed in” to the phylogenetic structure among our 293 S. Typhi H58 isolates, 
described by 45 of the assayed SNP loci that differentiate within the H58 cluster 
(Figure 3). The isolates were divided into 24 distinct H58 subtypes, with the majority 
(N=270) in 13 haplotypes (Figure 3). Most of the H58 subtypes (N=14), including the 
ancestral subtype A, included isolates harbouring the PST6 plasmid (Figure 3, solid 
shading). We have previously sequenced the genomes of 19 S. Typhi, including seven 
isolates from the H58 haplogroup (50), and observed the insertion of an IS1 
transposase between protein coding sequences STY3618 and STY3619 within all 
sequenced H58 S. Typhi genomes. This transposase was identical at the nucleotide 
level to the IS1 sequences within Tn9 in IncHI1 plasmids pHCM1 and pAKU_1, and 
shared a common insertion site in all seven H58 chromosomes sequenced (50). In the 
present study, our SNP assays included a probe targeting sequences within the IS1 
gene. Nearly all of the S. Typhi H58 isolates gave positive signals for this IS1 target 
(Figure 3; coloured or white), with the sole exception of six isolates from the H58 
ancestral node A, which also included three isolates that carried the PST6 plasmid and 
tested positive for IS1 (Figure 3, node A). This suggests that the PST6 plasmid was 
likely acquired by the common ancestor of S. Typhi H58 (Figure 3, node A), followed 
by transposition of IS1 into the S. Typhi chromosome, which is now conserved among 
all H58 strains tested. Thus the dominance of PST6 over other MDR IncHI1 plasmids 
(noted here and previously (40)) and the dominance of H58 over other S. Typhi 
haplotypes (noted here and previously (23, 44)) appears to be the result of a trans-
continental clonal expansion of MDR, PST6-bearing, H58 S. Typhi. 
 
Selective Advantages of IncHI1 PST6 
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These results suggest that the global spread of MDR typhoid since the mid-1990s is 
attributable to the spread of a single plasmid-strain combination. This raises the 
questions of why this particular combination has been so successful and why PST6 
has remained so closely associated with S. Typhi H58, especially since we were able 
to transfer PST6 plasmid pSTY7 from S. Typhi to E. coli and back to S. Typhi (data 
not shown) and given the evidence for previous IncHI1 plasmids co-circulating and 
spreading between S. Typhi strains (above). Since the drug resistance phenotype 
conferred by PST6 and is indistinguishable from most other IncHI1 plasmids, we 
hypothesised that PST6 may provide its S. Typhi host with some additional selective 
advantage, over and above that of drug resistance. To investigate what this might be, 
we introduced representative PST1 (pHCM1) and PST6 (pSTY7) IncHI1 plasmids 
from Vietnamese S. Typhi isolates into a common host strain via conjugal transfer. To 
facilitate manipulation in the laboratory, we chose the laboratory strain BRD948 as 
our common host, which is an attenuated strain derived from the S. Typhi strain Ty2 
(haplotype H10). BRD948 (PST1) was able to outcompete BRD948 (PST6), reaching 
a ratio of 3:1 after 4 days of competitive growth in LB broth (Figure 4a, black). We 
therefore hypothesized that the advantage conferred by PST6, if any, might be related 
to specific environmental conditions or to plasmid-strain interactions. To test the 
latter, we compared the growth of wildtype S. Typhi H1 (PST1) and S. Typhi H58 
(PST6) isolated from typhoid patients in Vietnam and Pakistan (listed in Table 6). 
Both H58 (PST6) strains were able to outcompete the H1 (PST1) strain, so that S. 
Typhi H1 was barely detectable after four days of competitive growth (Figure 4a; 
red). However plasmid-free H58 S. Typhi were also able to outcompete plasmid-free 
H1 S. Typhi (Figure 4a; blue), thus we cannot confirm an H58-PST6 interaction. 
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To screen for conditions in which PST6 confers an advantage over PST1, we used 
Biolog phenotyping arrays to compare the growth of plasmid-free S. Typhi BRD948 
to BRD948 (PST1) and BD948 (PST6) under a wide variety of conditions including 
various pH levels and osmotic/ionic strengths, and a wide variety of antibiotics and 
chemicals (52). As expected, both IncHI1 plasmids conferred enhanced growth in the 
presence of a wide range of antibiotics including amoxicillin, azlocillin, oxacillin, 
penicillin G, phenethicillin, chloramphenicol, streptomycin, gentamicin, tetracyclines, 
trimethoprim (Table S3). While neither plasmid conferred resistance to 
cephalosporins, the plasmid-bearing strains grew better than plasmid-free BRD948 in 
the presence of cephalosporins: cefazolin, cephalothin, and the third-generation 
cephalosporins cefotaxime, ceftriaxone and cefoperazone (Table S3), presumably due 
to the presence of the beta-lactamase gene blaTEM-1. When tested for their minimum 
inhibitory concentration (MIC) to clinically relevant drugs all isolates were fully 
susceptible to cephalosporins (MICs ≤ 0.125 to cefepime, cefotaxime and 
ceftazidime) and there was no evidence of extended spectrum beta-lactamase activity. 
Interestingly, BRD948 (PST1) was more resistant than BRD948 to a range of 
chemicals including the quinolones oxolinic acid and 5,7-Dichloro-8-hydroxy-
quinaldine; fungicides acriflavine, benserazide, captan and tolylfluanid; and toxins 
sodium cyanate and zinc chloride, which may be due to non-specific efflux. 
Resistance to quinolones is a marker for reduced susceptibility to fluoroquinolones 
(53, 54), however the PST1 plasmid conferred no increase in MIC to the quinolone 
Nalidixic acid (MIC 2mg/L for BRD948, BRD948pHCM1 and BRD948pPST6); a 
similar lack of resistance (MIC 0.008 mg/L) was seen for ciprofloxacin. The only 
other difference between the two plasmid-bearing strains was that BRD948 (PST6) 
exhibited increased resistance to osmotic stress (3-5% NaCl or 6% KCl) (Table S3).  
p14/52 
 
We hypothesised that the osmotolerant properties of PST6 may be explained by the 
presence of two putative transporters encoded within a composite transposon, 
Tn6062, found in PST6 but not PST1 plasmids (see Figure 5a; this transposon was 
called Ins1056 in (40)). Tn6062 is one of very few differences in gene content we 
identified between the sequenced plasmids pHCM1 (PST1) and pAKU_1 (PST7) (34, 
40), and we have previously observed that Tn6062 was present in all IncHI1 plasmids 
of the PST6, PST7 and PST8 sequence types (40). In the present study, Tn6062 was 
detected by the positive signals of two loci within the SPAP0105 gene. All PST6 
plasmids in our study carried Tn6062, as did the novel subtype of PST1 (57Laos) and 
two of the three PST8 plasmids (Peru, 1981) (Table 5). To determine if Tn6062 was 
responsible for the osmotolerance conferred on S. Typhi BRD948 by the PST6 
plasmid, we cloned the two genes in Tn6062 (SPAP0105 and SPAP0196; see Figure 
5a) into a low copy number vector pAYCY184 and assessed their effect on S. Typhi 
BRD948 in high salt concentration medium (0.8M NaCl LB broth, approx. 4.7% 
NaCl). S. Typhi BRD948 (PST1) was unable to grow under these conditions (Figure 
5b; grey). However in the presence of PST6, the same host strain grew easily (Figure 
5b; blue), confirming the phenotyping array result. BRD948 (pAYCY184-Tn6062) 
was able to grow at a slightly lower rate than BRD948 (PST6) (Figure 5b, blue), 
while BRD948 carrying the empty pAYCY184 vector was unable to grow at all 
(Figure 5b, black). Therefore the transposon Tn6062 carried by PST6 confers an 
osmotolerance phenotype on S. Typhi in addition to the MDR phenotype.
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Discussion 
 
The Spread of MDR Typhoid 
Our analysis indicates that the IncHI1 plasmids responsible for the vast majority of 
MDR in S. Typhi are very closely related to IncHI1 plasmids causing MDR in other 
enteric pathogens. These plasmids share a recent common ancestor approximately six 
decades old and have evolved into several distinct lineages via a process of mutational 
divergence, followed by acquisition of resistance elements, then further mutational 
divergence (Figure 1). Simultaneous SNP typing of plasmid and host enabled us to 
differentiate between the clonal expansion of an MDR S. Typhi host strain, and 
independent acquisitions of the same MDR plasmids by distinct S. Typhi hosts. PST8 
was found in S. Typhi of two distinct haplotypes, co-circulating in Peru in 1981, while 
PST2 was found in three distinct S. Typhi haplotypes in Asia between 1972-1976 
(Table 5). This confirms that the spread of MDR typhoid in the 1970s and 1980s was 
due to the multiple acquisitions of IncHI1 plasmids in the S. Typhi population, 
involving multiple IncHI1 plasmids and the spread of individual plasmid types 
between S. Typhi haplotypes co-circulating in the same spatio-temporal location. One 
of the PST2-S. Typhi combinations (haplotype H42) was later detected among two 
strains from Africa in 2003-2004, suggesting that an individual IncHI1 plasmid may 
be able to persist in a single host strain for decades (Table 5). In stark contrast, all 193 
PST6 plasmids were observed in S. Typhi of the H58 haplotype, and virtually all 
MDR S. Typhi observed after 1995 belonged to the same PST6-H58 clone, indicating 
that the recent global spread of MDR typhoid is the result of the clonal expansion of 
PST6-H58 S. Typhi. Since humans are the only known reservoir for S. Typhi (55), it 
is likely that trans-continental spread of this clone depends on international travel or 
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migration. If this is the case it will be particularly difficult to control since S. Typhi 
can be transmitted by asymptomatic carriers (56, 57), who are usually unaware of 
their status and are difficult to detect (58, 59). 
 
The S. Typhi H58 - PST6 Association and Selection 
Our data suggests that MDR among H58 S. Typhi is exclusively conferred by PST6 
IncHI1 plasmids, and that this association can be explained by a single acquisition 
event in which the PST6 plasmid was acquired by the most recent common ancestor 
of S. Typhi H58 (Figure 3). Evidence from IS1 and PST6 content of S. Typhi H58 
isolates suggests that the common ancestor of H58 carried PST6, implying that the 
expansion of S. Typhi H58 did not begin until after acquisition of the plasmid (Figure 
3). Evidence from sequence data indicates that the common ancestor of three PST6 
plasmids sequenced from H58 strains in 2003-2004 existed around 1999 (Figure 1). 
This further supports the idea that PST6 was acquired once in H58 in the early 1990s, 
and its presence in current H58 isolates is due to co-segregation with its host strain as 
opposed to repeated introduction of PST6 plasmids into H58.  
 
This tight association suggest PST6 may confer a strong selective advantage upon its 
H58 S. Typhi host. Since PST6 plasmids confer the same antimicrobial resistance 
phenotypes as other IncHI1 plasmids, it is unlikely that the expansion of H58 is due to 
selection for MDR alone. On the other hand, the PST6 MDR plasmid appears to have 
been lost from H58 S. Typhi in some areas where the switch to fluoroquinolones was 
made, including Nepal and Vietnam (42, 60, 61). Whereas, in locations where 
fluoroquinolones are not readily available and the use of chloramphenicol has been 
maintained for typhoid treatment, for example in Kenya, the plasmid has been 
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maintained in the S. Typhi population (18, 23). This confirms that antimicrobial use 
exerts a strong selective pressure for maintenance of the IncHI1 plasmid among S. 
Typhi and indicates that in the absence of such pressure, any additional advantages 
conferred (e.g. the increased osmotolerance we observed) is not enough to maintain 
the PST6 plasmid.  
 
This highlights the dynamic and adaptive nature of antimicrobial resistance in 
bacterial pathogen populations, but it does not rule out the possibility that PST6 may 
have conferred an additional fitness advantage over other MDR IncHI1 plasmids 
when the selection for MDR was strong. Data from southern Vietnam in the mid-
1990s suggests there was a shift from one IncHI1 plasmid (pHCM1; PST1), which 
had been circulating at high frequency in the local S. Typhi population, to another 
(pSTY7; PST6) in 1995 (30). The plasmid pHCM1 came from an S. Typhi H1 strain 
but we were unable to confirm the haplotype of the host strain from which pSTY7, 
the prototype PST6 plasmid, was isolated since the plasmid had been transferred into 
E. coli for storage. However since all 193 PST6 we detected were found in S. Typhi 
H58, including 135 isolates from Vietnam, it is highly likely that the original host of 
pSTY7 was H58. Thus the competition assays we performed, using PST6 plasmid-
bearing H58 strains and PST1 plasmid-bearing H1 strains from Vietnam, may be a 
reasonable approximation for the competition that occurred in the endemic S. Typhi 
population in Vietnam in the early 1990s. The assays showed that, under laboratory 
conditions, both PST6-H58 S. Typhi tested were able to strongly outcompete a PST1-
H1 strain (Figure 4a). However the role of the plasmid remains unresolved, since 
plasmid-free H58 S. Typhi were also able to outcompete plasmid-free H1 S. Typhi 
(Figure 4a).  
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Plasmid-Strain Interactions 
To investigate strain-plasmid interactions thoroughly, extensive competition 
experiments involving numerous plasmid-bearing isolates (as independent biological 
replicates) and conjugal transfer of plasmids between strains of different haplotypes 
followed by extensive subculturing (to account for plasmid-strain adaptations), will 
need to be performed under a variety of growth conditions. This is beyond the scope 
of our study, however it is interesting to note that in the common strain background of 
BRD948 and under laboratory conditions, the situation was reversed such that PST1 
appeared to have an advantage over PST6 (Fig. 5A; black). This was unexpected 
given the competitive advantage exhibited by wildtype PST6-H58 over PST1-H1 and 
the current real-world dominance of PST6. This could be due to plasmid-strain 
interactions, or the vast differences between laboratory growth conditions and the 
real-world niches in which S. Typhi needs to grow.  
 
We initially used a common strain background to ensure that any observed 
differences were due entirely to the differences between PST6 and PST1 plasmids. 
However this may not be an accurate reflection of real-world plasmid competition 
dynamics. While the fitness of a particular host strain is usually reduced when a large 
plasmid such as IncHI1 is acquired, fitness can then increase as the plasmid and strain 
adapt to the new combination during subsequent generations, resulting in a fitness 
level equal to or greater than the original plasmid-free strain (62). This increased 
fitness can be due to adaptations in the plasmid and/or the host strain during co-
evolution over hundreds of generations (62, 63). While the PST1 and PST6 plasmids 
used in the experiments had been initially isolated in S. Typhi, they had been stored in 
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E. coli for some time prior to conjugal transfer into S. Typhi BRD948. It is therefore 
possible that the plasmids were no longer well-adapted to S. Typhi, or that BRD948 
was not well adapted to the IncHI1 plasmids. After introduction of the plasmids to 
BRD948, the recipient strains were kept in glycerol stocks prior to performing 
competition assays, thus our experiments may not accurately reflect the real-world 
situation in which new plasmid-host combinations are able to equilibrate over many 
generations, resulting in fitter strains (62). It is also possible that S. Typhi BRD948, 
which is attenuated by a deletion of aroC, aroD and htrA and was derived from a 
strain that has been grown in the laboratory for many decades (64), is not 
representative of S. Typhi currently circulating in typhoid endemic areas. 
 
Tn6062 and Osmotolerance 
Despite the uncertainties surrounding strain-strain differences, plasmid-strain 
interactions and real-world selection pressures, our analyses revealed that PST6 also 
confers osmotolerance on its S. Typhi host, via Tn6062. The transposon Tn6062 is 
made up of two genes, betU and SPAP0105, flanked by IS1 elements in direct 
orientation (Fig. 4A). The conserved gene SPAP0105 contains a signal peptide 
sequence and four probable transmembrane helices, suggesting it may be an outer 
membrane protein, however it contains no protein domains of known function. BetU 
contains a betaine-choline-carnitine transporter family domain and encodes a betaine 
uptake system, capable of transporting glycine betaine and proline betaine (65). It was 
first described in E. coli strains causing polynephritis (ascending urinary tract 
infection) and is believed to be an osmoregulator, allowing E. coli to survive the high 
osmolarity and urea content in urine (65). However the gene is distributed among E. 
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coli with a range of pathogenic phenotypes, so its osmoprotectant properties may be 
useful in other environmental contexts (66).  
 
It is possible that enhanced osmotolerance may enhance facilitate the survival of S. 
Typhi in specific niches inside within the human body, including the gut, gall bladder, 
urinary tract or liver, or in the external environment. S. Typhi invades via the 
intestinal epithelium (67) and can establish chronic asymptomatic carriage in the gall 
bladder (68). The bacterium is shed in faeces (68) and urine (69) and has recently 
been detected in the liver of chronic carriers (70). S. Typhi can be transmitted via 
contaminated water, but it can be difficult to culture from water samples. Little is 
known about the mechanisms required for survival of S. Typhi in the environment. It 
is possible that the ability to grow in the presence of high salt concentrations might 
enhance the ability of S. Typhi to continue replicating in certain environments outside 
the host, which may lower the infectious dose or enhance the possibility of 
transmission by increasing the level of S. Typhi contamination in a given 
environment. 
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Conclusions 
The global spread of MDR typhoid since the mid-1990s is most likely due to clonal 
expansion of a single plasmid-strain combination, namely S. Typhi H58 bearing the 
IncHI1 PST6. This stands in stark contrast with patterns of MDR typhoid in the 
1970s-1980s, when distinct IncHI1 plasmids were present in distinct S. Typhi hosts 
and spread between co-circulating S. Typhi lineages. The success of the H58-PST6 
clone remains unexplained, however we found PST6 plasmids conferred the 
additional phenotype of osmotolerance via Tn6062, which may contribute to the 
selection of PST6 over other IncHI1 plasmids previously circulating among S. Typhi.  
 
 
Materials and Methods 
 
Bacterial isolates and DNA extraction 
The bacterial isolates analysed by SNP array are summarized in Table 1 and listed in 
full in Supplementary Table 1. DNA was extracted using Wizard Genomic DNA 
purification kits (Promega) according to manufacturer’s instructions. Details of the 
four isolates used for competition experiments are listed in Table 5. 
 
BRD948 is the attenuated Ty2-derived strain CVD908-htrA, which has deletion 
mutations in aroC, aroD, and htrA (64). The growth of BRD948 on LB agar or in LB 
broth was enabled by supplementation with aromatic amino acid mix (aro mix) to 
achieve the final concentration of 50 M L-phenylalanine, 50 M L-tryptophan, 1 M 
para-aminobenzoic acid and 1 M 2,3-dihydroxybenzoic acid. 
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Identification and phylogenetic analysis of IncHI1 SNPs 
Plasmid sequences listed in Table 1 were downloaded from EMBL. SNPs between 
finished plasmid sequences were identified using the nucmer and show-snps 
algorithms within the MUMmer 3.1 package (71), via pairwise comparisons against 
pAKU_1 as the reference sequence. To identify SNPs in S. Typhi PST6 IncHI1 
plasmids, 36 bp single-ended Illumina/Solexa sequencing reads from S. Typhi strains 
E03-9804, ISP-03-07467 and ISP-04-06979 were aligned to the pAKU_1 sequence 
using Maq (72) and quality filters as described previously in (50). SNPs called in 
repetitive regions or inserted sequences were excluded from phylogenetic analysis, so 
that phylogenetic trees were based only on the conserved IncHI1 backbone sequence. 
This resulted in a total of 347 SNPs, which were analysed using BEAST (47) to 
simultaneously infer a phylogenetic tree and divergence dates (using the year of 
isolation of each plasmid as listed in Table 1, resulting tree in Figure 1). Parameters 
used were as follows: generalised time reversible model with a Gamma model of site 
heterogeneity (4 gamma categories); a relaxed molecular clock with uncorrelated 
exponential rates (47), a coalescent tree prior estimated using a Bayesian skyline 
model with 10 groups (73), default priors, 20 million iterations.  
 
SNP typing analysis 
The chromosomal haplotype of S. Typhi isolates was determined based on the SNPs 
present at 1,485 chromosomal loci identified previously from genome-wide surveys 
(44, 50) and listed in (23, 42). IncHI1 plasmid haplotypes were determined using 231 
SNPs located in the conserved IncHI1 backbone sequence, listed in Table S2 (note 
these do not include SNPs specific to pMAK1 or pO111_1 which were not available 
at the time of assay design; however additional SNPs identified via plasmid MLST 
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(40) were included, see Table S2). Resistance gene sequences were interrogated using 
additional oligonucleotide probes, listed in (45). All loci were interrogated using a 
GoldenGate custom array according to the manufacturer’s standard protocols 
(Illumina), as described previously (23, 42, 45). SNP alleles were concatenated to 
generate two multiple alignments, one each for chromosomal and IncHI1 plasmid 
SNPs. Maximum likelihood phylogenetic trees (Figures 2-3) were fit to each 
alignment using RAxML (74) with a GTR+Γ model and 1,000 bootstraps.  
 
PCR 
PCR primers were designed using Primer3 (75) according to the following criteria: 
melting temperature 56°C, no hairpins or dimers affecting 3’ ends, no cross-dimers 
between forward and reverse primers. Primer sequences are given in Table 3. PCRs 
were performed on a TETRA DNA Engine Peltier Thermal Cycler (MJ Research) 
with a reaction consisting of 1.2 μl 10X of Mango PCR buffer 10x, 1.5 mM of MgCl2, 
25 μM of each dNTP, 1.25 U of Mango Taq (Bioline), 0.3 μM of each primer, 1.0 μl 
of DNA template (approx. 100 ng) and nuclease free water to in a the total reaction 
volume of 12 μl. Cycling conditions were as follows: 5 min at 94°C, 30 cycles of 15s 
at 94°C, 15s at 58°C, and 60s at 72°C; final extension of 5 min at 72°C. 
 
Plasmid transfer 
The transfer of pHCM1 and pSTY7 from respective E. coli transconjugants to the 
attenuated S. Typhi BRD948 was performed by cross-streaking onto LB agar 
supplemented with aro mix and incubating at 37C overnight. The growth was 
harvested, resuspended in 2 ml of dH20, plated on MacConkey agar containing 
streptomycin (1 g/ml or 5 g/ml) and chloramphenicol (5 g/ml or 20 g/ml) and 
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incubated overnight at 37C. BRD948 transconjugants were confirmed by 
antimicrobial susceptibility patterns (disk diffusion) and colony PCR specific for 
BRD948 background (primers 5939-5’-CGTTCACCTGGCTGGAGTTTG-3’ and  
5940-5’-CATGCCAGCAGCGCAATCGCG-3’) and pHCM1 or pSTY7 plasmids 
(Insert1056L- 5’-TAGGGTTTGTGCGGCTTC-3’ and Insert1056R-5’-
CCTTCTTGTCGCCTTTGC-3’).  
 
Competition assays in common strain background 
The competition between BRD948 (pHCM1) and BRD948 (pSTY7) was started in 
equal inoculums of roughly 5x10
3
 CFU each in 10 mL of LB broth supplemented 
with aro mix and chloramphenicol (5 μg/mL). The culture was incubated for 16 hours 
at 37°C with shaking. Approximately 10
4
 CFU of this culture were then used to 
inoculate the next passage. The cultures were passaged for a total of 4 days. Samples 
were collected at time point 0 (at the time of initial inoculation) and after 1, 2, 3 and 4 
days of passage, diluted and spread on LB agar supplemented with aro mix. Sixty-
four colonies from each sample were randomly picked and tested by PCR to identify 
their plasmid type (see below). The entire competition assay was performed in 
triplicate, i.e. beginning with three initial cultures of equal inoculums of the two 
strains. The colony PCR was perform using standard condition (see PCR section 
above) with three primers HCM1.DF 5’-CGATTTGTGAAGTTGGGTCA-3’, 
HCM.DR2 5’- CAACCTGGGCAGGTGTAAGT-3’ and HCM.DR3 5’- 
TTCGTTACGTGTTCATTCCA-3’. Expected sizes of PCR products were 511 bp for 
BRD948 (pHCM1) and 285 bp for BRD948 (pSTY7). 
 
Competition assays using wildtype strains 
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Eight individual competitive growth assays were performed; H58c vs. H58e, H58c vs. 
H1, H58e vs. H1, H58c-ST6 vs. H58e-ST6, H58c-ST6 vs. H1-ST1, H58e-ST6 vs. 
H1-ST1, H58c-ST6 vs. H58e and H58e-ST6 vs. H58c. The corresponding strains for 
each of the haplotypes and plasmid types is shown in Table 5. Bacterial isolates were 
recovered from frozen stocks onto Luria-Bertani (LB) media, supplemented with 20 
mg/ml of chloramphenicol for strains with MDR plasmids. Individual colonies were 
picked and used to inoculate 10 ml of LB broth, which were incubated overnight at 
37
o
C with agitation. Bacterial cells were enumerated the following day by serial 
dilution and plating. Equivalent quantities of the two competing S. Typhi strains were 
inoculated into 10 ml of LB broth and were incubated as before (Day 0). The 
competition assays were conducted by growing the mixed bacteria to stationary phase 
and then passaging them into 10 ml of LB broth in a 1:1000 dilution in triplicate over 
six days. The total colony forming units per ml were calculated for each assay by 
serial dilution and plating on LB media with and without chloramphenicol (20 mg/ml) 
to determine the proportion of strains with and without plasmids on Day 6. 
Additionally, 1 ml of media containing bacteria from each of the triplicates was stored 
at -80
o
C at each time point. DNA was extracted from the frozen samples by boiling 
for 10 minutes, samples were centrifuged at 8,000 rpm [give centrifugal speed in x g] 
in a microfuge for 5 minutes. The supernatant was removed and used as template in 
all of the subsequent competitive real-time PCR reactions, which were performed on 
each template in duplicate. 
 
Real-time PCR for quantitation of wildtype strains in competition assays 
We performed two individual competitive real-time PCRs (Taqman system) with 
LNA probes to calculate the proportions of S. Typhi H1 vs. S. Typhi H58 and S. 
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Typhi H58c vs. S. Typhi H58e. These assays were performed to accurately calculate 
the relative proportion of the strains in all competitive assays, including those that 
could not be calculated by plating alone. The haplotype specific primers and probes 
were designed using Primer Express Software (Applied Biosystems) and 
manufactured by Sigma-Proligo (Singapore). Primer and probe sequences were as 
follows; (capital letters indicate the position of LNA and the bold letters indicate the 
SNP position) H58 vs H1 (99 bp amplicon): F(71-83)-CCGAACGCGACGG, R(169-
157)-TGCGGCACACGGC  and probe 5’-FAM-ccggtAatGgtAatGaagc-BHQ1 (S. 
Typhi H1) and 5’-Hex-ccggtAatAgtAatGaagc (S. Typhi H58); H58c vs H58e (89 bp 
amplicon): F(60-75)-ACCCTGCACCGTGACC, R-(148-135)-
GCATGATGCCGCCC and probe 5’-FAM-ttcCagGccAtgAcgc –BHQ1 (S. Typhi 
H58c) and 5’-HEX-ttcCagAccAtgAcgc-BHQ1 (S. Typhi H58e). PCR amplification 
were performed using a light cycler (Roche, USA), with hot start Taq polymerase 
(Qiagen, USA) under the following conditions, 95
o
C for 15 minutes and 45 cycles of 
95
o
C for 30 seconds, 60
o
C for 30 seconds and 72
o
C for 30 seconds. As the primer 
locations were identical for the internal competitive PCR assay, the efficiency of the 
PCR was also considered to be identical. Therefore, proportions of strains at the 
various time points throughout the assay were calculated by taking the mean of six Cp 
values (each competition assay was performed in triplicate and the PCR was 
performed in duplicate). The Mean Cp values for each competitive assay was 
converted into a proportion (strain A) using the following calculation: Proportion 
strain A = 1/(2 
-ΔCp 
 + 1) , where ΔCp = Cp (strain B) – Cp (strain A). 
 
Phenotype Microarrays 
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Phenotype microarrays of osmotic/ionic response (PM 9), pH response (PM 10) and 
bacterial chemical sensitivity (PM 11 to 20) were performed as described previously 
by Biolog Inc. (Hayward, California USA) (52). BRD948 was used as a reference for 
comparison with BRD948 (pHCM1) or BRD948 (pSTY7) test strains to identify the 
phenotypes affected (either gained or loss) by the presence of IncHI1 plasmid 
pHCM1 (ST1) or pSTY7 (ST6). 
 
The three strains were pre-grown on LB (Luria-Bertani) agar plates supplemented 
with 1X of an aromatic amino acid mix (a 50X aromatic amino acid mix consisted of 
50 μM L-phenylalanine, 50 μM L-tryptophan, 1 μM para-aminobenzoic acid and 1 
μM 2,3-dihydroxybenzoic acid). Sterile cotton swabs were used to pick colonies and 
suspend them in 10 ml IF-0a (Biolog), the optical density of which was then adjusted 
to 0.035 absorbance units at 610 nm.  A total of 750 μl of this cell suspension was 
diluted 200 fold into 150 ml IF-10 (Biolog), containing 1X aromatic acid mix. PM 
microtitre plates 9-20 were inoculated with 100 μl of the cell suspension and 100 μl of 
Biolog media supplemented with aromatic amino acid (containing 1.2X of Biolog 
media, 22 ml of sterile water and 3 ml of 50X aromatic amino acid mix) per well. 
Microtitre plates were then incubated at 37°C for 48 h in the Omnilog (Biolog Inc) 
and each well was monitored for colour change (kinetic respiration). Tests were 
performed in duplicate and the kinetic data was analysed using the OmniLog PM 
software set (Biolog Inc). A lower threshold of 80 omnilog units (measured as area 
under the kinetic response curve) was set, and the phenotypes of each of the three 
strains were compared. 
 
Cloning and growth curves 
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The fragment of two CDSs within Tn6062 of pSTY7 (3405 bp) was amplified using 
two primers IS1056-03 (5’-CAGGCACCGTTTTCTTATTAGAATCTTCGCCACT-
3’) and IS1056-04 (5’- TCATTGAACTTTGCTACCCTGA-3’). The pACYC184 
fragment (2033 bp) containing its p15A ori and chloramphenicol resistant gene (cmR) 
was amplified using pACYC184-01 (5’-AAAATTACGCCCCGCCCTGC-3’) and 
pACYC184-03 (5’- TAATAAGAAAACGGTGCCTGACTGCGTTAGCA-3’). The 
two fragments were then fused together by overlapping primer extension PCR 
(pACYC184-03 and IS1056-03 were two overlapping primers) using pACYC-01 and 
IS1056-04 primers. All three PCRs above were performed using PfuUltra II Fusion 
HS DNA Polymerase (Agilent, former Stratagene, UK) to achieved highly accurate 
amplification. The PCRs were set up following the manufacturer’s manual with the 
specific annealing temperature of 58C and extension time of 45s for Tn6062 and 
pACYC184 fragments or 1.5 min for the fusion fragment. The fused PCR product 
was re-circularised by T4 ligase (New England BioLabs, UK) to form 
pACYC184tet::Tn6062 and electroporated to BRD948. The pACYC184 fragment 
was also re-circularised to form the empty vector pACYC184tet and electroporated 
to BRD948.  
 
Overnight bacterial cultures of BRD948 (pHCM1), BRD948 (pSTY7), BRD948 
(pACYCtet) and BRD948 (pACYCtet::Tn6062) were diluted by distilled water to 
the cell suspension of 0.1 OD600  before 1 μl of the cell suspension was inoculated into 
200 μl of 0.8M NaCl LB broth (supplemented with aromatic amino acid mix) in a 
well of a 96-well plate. Each strain was inoculated to 6 wells (6 biological replicates). 
The bacteria were grown at 37C with shaking at 300 rpm and OD600 was measured 
automatically every 15 minutes for 24 hours in the Optima plate reader (BMG 
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Labtech, Germany). The absorbance data were collected and saved in Excel format 
for graphing. 
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Plasmid Host 
Year of 
isolation 
Plasmid 
type Accession Citation 
pHCM1 S. Typhi strain CT18 1993 PST1 AL513383 (49) 
pAKU_1 S. Paratyphi A strain AKU_12601 2003 PST7 AM412236 (34) 
R27 S. Typhimurium 1961 PST5 AF250878 (76) 
pMAK1 S. Choleraesuis strain L-2454 2002 PST1 AB366440 - 
pO111_1 E. coli O111:H- strain 11128 2001 PST1 AP010961 (77) 
p9804_1 S. Typhi strain E03-9804 2004 PST6 ERA000001 (50) 
p7467_1 S. Typhi strain ISP-03-07467 2003 PST6 ERA000001 (50) 
p6979_1 S. Typhi strain ISP-04-06979 2004 PST6 ERA000001 (50) 
 
Table 1. IncHI1 plasmid sequences analysed in this study. 
 
 
p31/52 
 
IncHI1 plasmid 
sequence type PST1 PST5 PST6 PST6 PST7 PST8 
Plasmid or 
isolate pHCM1 pMAK1 p0111_1 R27 p6979 pSTY7 pAKU1 81918 
81863, 
81424 
Bacterial host T C Ec Tm T T Pa T T 
Tn10 insertion B B B C A A A A A 
  sequence data B B B C A n/a A n/a n/a 
  N (Tn10 - 
         HCM1.247) yes n/d n/d no no no no no no 
  O (tetD - 
         SPAP0276) no n/d n/d no yes yes yes yes yes 
  P (SPAP0261 - 
         Tn10) no n/d n/d no yes yes yes yes yes 
Tn9 insertion B B B no A A A no A 
  sequence data B B B no A n/d A n/a n/a 
  J (cat - trhN) no n/d n/d no yes yes yes no yes 
  K (mer - trhI) no n/d n/d no yes yes yes no yes 
  M (cat -     
       HCM1.203) yes n/d n/d no no no no no no 
  L (insA - tetA) yes n/d n/d no no no no no no 
Tn21 into Tn9 yes yes yes no yes yes yes no yes 
  sequence data yes yes yes no yes n/d yes n/a n/a 
  H (tnpA - Tn9) yes* n/d n/d no yes yes yes no yes 
  I (merR - Tn9) yes* n/d n/d no yes yes yes no yes 
bla/sul/str into 
Tn21 yes yes yes no yes yes yes no yes 
  sequence data yes yes yes no yes n/d yes n/a n/a 
  G (strB – 
         tniAdelta) yes yes yes no yes n/d yes no yes 
strAB 2
nd
 copy no no no no no no yes yes yes 
  sequence data no no no no no n/d yes n/a n/a 
  Q (strB – 
        SPAP0228) no n/d n/d no no no yes yes yes 
[using + and – designations in the table might be easier?] 
Table 3. Resistance gene insertion sites in IncHI1 plasmids inferred from a 
combination of PCR and sequencing. Summaries of five insertion patterns are 
shown in bold italics; these are inferred from sequence data where available (italics) 
and PCR using primers shown in Table 3 (labelled G-Q). T = Salmonella enterica 
serovar Typhi, C = Salmonella enterica serovar Choleraesuis, Tm = Salmonella 
enterica serovar Typhimurium, Pa = Salmonella enterica serovar Paratyphi A, Ec = 
E. coli O111:H-. *Distinct amplicon size for PST1; n/d PCR not done; n/a sequence 
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data not available. “strAB 2nd” copy refers to the insertion of streptomycin resistance 
genes strAB directly into the plasmid backbone, not as part of the bla/sul/str element. 
 
 
 
  Forward primer Length in pAKU_1 
(bp) 
Length in pHCM1 
(bp)   Reverse primer 
G GATGGAGAAGAGGAGCAACG 989 989 
 TTCGTTCCTGGTCGATTTTC 
H GTGCTGTGGAACACGGTCTA 271 1,598 
 TCATCAACGCTTCCTGAATG   
I ACGAAAGGGGAATGTTTCCT 163 1,490 
 CGAGTGGGAATCCATGGTAG   
J CAAAATGTTCTTTACGATGCC 2,219 none 
 CCAGACAGGAAAACGCTCA   
K CTGTGCCGAGCTAATCAACA 1,314 none 
 ACGAAAGGGGAATGTTTCCT   
L TTTTAAATGGCGGAAAATCG none 1,872 
 GCCAGTCTTGCCAACGTTAT   
M GGGCGAAGAAGTTGTCCATA none 2,195 
 ATTCGAGCAAAACCATGGAA   
N CGGGATGAAAAATGATGCTT none 2,180 
 GGTCGGTGCCTTTATTGTTG   
O GCGTACAAAAGGCAGGTTTG 1,823 none 
 GCTTGATGATGTGGCGAATA   
P TGGTCGGTGCCTTTATTGTT 1,899 none 
 GGGCGTCAGAGACTTTGTTC   
Q TTCGCCCGATATAGTGAAGG 1,923 none 
 CTAACGCCGAAGAGAACTGG   
 
Table 3. PCR primers for detection of resistance gene insertion sites 
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Region 
No. 
countries 
pre-
1970s 
1970s-
1980s 
1990s 
2000-
2007 
Total 
isolates 
South & Central America 4 0 6 3 2 11 
Central, Southern, East Africa 7 10 3 3 26 42 
North Africa 3 11 1 8 5 25 
West Africa 11 28 0 6 12 46 
East Asia 8 5 8 22 187 222 
Indian Subcontinent 3 0 3 1 66 70 
Middle East 3 0 0 0 31 31 
Europe 5 1 1 2 2 6 
Unknown - 1 0 0 0 1 
Total 44 56 22 45 331 454 
  
TTable 4. Summary of 454 S. Typhi isolates analysed in this study. 
Note full details of these S. Typhi isolates, and eight E. coli transconjugants, are given 
in Supplementary Table 1. 
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Isolate Year Country Chr Plas IS
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76-54 1976 Chile H50 7654                                     
78-851 1978 Tunisia H9 78851                                     
CT18 1993 Vietnam H1 PST1                                     
76-1406 1976 Indonesia H42 PST2                                     
75-2507 1975 India H55 PST2                                     
77-302 1977 India H55 PST2                                     
77-303 1977 India H55 PST2                                     
72-1907 1972 Vietnam H68 PST2                                     
72-1258 1972 Mexico H11 PST3                                     
73-1102 1973 Vietnam H87 PST4                                     
81-863 1981 Peru H50 PST8                                     
81-424 1981 Peru H77 PST8                                     
81-918 1981 Peru H77 PST8                                     
57Laos 2000* Laos H1 57Laos                                     
03-4747 2003* Togo H42 PST2                                     
04-6845 2004* Benin H42 PST2                                     
 
Table 5. Chromosome, plasmid and resistance gene details of drug resistant S. 
Typhi isolated up to 1993*. Colour indicates the presence of transposase or 
resistance-associated genes (given in columns) in each S. Typhi isolate (rows). 
*Indicates the only MDR S. Typhi isolated after 1993 that were not of the H58 
haplotype or PST6 IncHI1 haplotype. 
 
 
Strain ID Haplotype node Plasmid Year Location 
1727 H58-C none 2004 Pakistan 
BJ4 H58-E1 none 2004 Southern Vietnam 
255 H58-C PST6   Unknown? 
AG45 H58-E1 PST6  2004 Southern Vietnam 
TY36 H1 none ?? Southern Vietnam 
DTC52 H1 PST1  Southern Vietnam 
 
Table 6. S. Typhi isolates used in competition assays. Haplotype nodes are labelled 
as in Figure 2a. 
Format t ed:  Hi ghl i ght
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Figure legends 
 
 
 
Figure 1. Phylogenetic tree for IncHI1 plasmid sequences. 
Phylogenetic tree based on 347 SNPs identified among 8 publicly available IncHI1 
plasmid sequences, constructed using BEAST (with 20 million iterations, 4 replicate 
runs, exponential clock model). Terminal nodes are labelled with the date of isolation, 
which were input into the BEAST model in order to estimate divergence dates for 
internal nodes (open circles, labelled with divergence date estimates; brackets indicate 
95% highest posterior density interval). Insertion sites (grey) are based on sequence 
data and verified (except for pO111_1 and pMAK1) by PCR. Precise insertion sites 
and PCR primers for verification are given in Tables 2-3. Four major plasmid groups, 
PST1, PST5, PST6, PST7, are coloured as labelled. 
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Figure 2. Phylogenetic trees of S. Typhi chromosome and IncHI1 plasmid. 
(a) Phylogenetic tree indicating chromosomal haplotypes of 454 S. Typhi isolates. 
Nodes indicate the detection of S. Typhi isolates, node sizes are scaled to the number 
of isolates detected, which is indicated with numeric labels. Unfilled circle indicates 
tree root; reference isolates used to define the S. Typhi SNPs are shown as grey nodes, 
labelled with the isolate name. Colours indicate the presence of IncHI1 plasmids 
within S. Typhi isolates of that haplotype; numbers represent the number of isolates at 
each node, different colours indicate different IncHI1 plasmid haplotypes 
corresponding to the tree in (b); black indicates no IncHI1 plasmid found in any strain 
of that particular chromosomal haplotype. Note that most of the nodes colour-coded 
to represent plasmid type also contain S. Typhi isolates with no plasmid, and the 
colours do not represent the proportion of strains harbouring the plasmid. 
p37/52 
(b) Phylogenetic tree of IncHI1 plasmids for 201 genotyped MDR S. Typhi. Coloured 
leaf nodes represent plasmid haplotypes that have been found in S. Typhi. 
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Figure 3. Phylogenetic tree of the H58 haplogroup of S. Typhi. Dashed line 
indicates where this tree joins into the larger phylogenetic tree of S. Typhi (shown in 
Figure 1). The two major H58 lineages are indicated by colour (blue, lineage I; red, 
lineage II; purple, common ancestor of both). Nodes are labelled with strain names 
(outer nodes representing sequenced strains; see (50)), haplotype (H followed by 
number) as defined in (44)) or letters indicating nodes resolved by SNP typing. Node 
sizes indicate the relative frequency of each haplotype node within the study 
collection of 269 H58 S. Typhi isolates, according to the scale provided. The 
proportion of isolates in each node carrying the PST6 plasmid and IS1 (solid colour), 
IS1 only (white) or neither (grey) is indicated by shading. 
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Figure 4. Competitive growth assays S. Typhi H58 and H1 with and without 
IncHI1 plasmids 
The dynamics of three competitive growth assays conducted over four days of 
sequential sub-culture. (A) Competition between PST1 and PST6 plasmid-bearing S. 
Typhi, including competition in a common strain background (attenuated laboratory 
strain S. Typhi BRD948; haplotype H10) and wildtype S. Typhi haplotype-strain 
combinations. (B) Competition between wildtype S. Typhi H58 strains with and 
without PST6 plasmids. For BRD948 assays, the proportion of PST1- and PST6-
bearing bacteria at each time point was calculated by streaking an aliquot of the 
sample onto agar plates and testing random colonies using a PCR that differentiates 
PST1 and PST6. For S. Typhi haplotype H58 vs H1 assays, the proportion of H58 and 
H1 chromosomes at each time point was calculated by quantifying the relative 
abundance of two alleles at a SNP locus that differs between H58 and H1 S. Typhi, 
p40/52 
using quantitative PCR. For all assays, experiments were replicated 4-5 times; data 
points represent the mean proportion of the PST6-bearing strain (underlined in the 
legend) and error bars show the standard deviation of the proportion of the PST6-
bearing strain. 
 
 
Figure 5. Tn6065 and its effect on osmotolerance of S. Typhi BRD948 
(A) Schematic diagram of Tn6062 showing the two flanking IS1 and the internal 
CDSs (based on nucleotide sequence of pAKU_1). The two black arrows represent 
primers used to clone the putative transporters to pACYC184. 
(b) Growth curves showing the osmotolerance of BRD948 (pSTY7; PST6) and 
BRD948 (pACYC184tet::Tn6062) in 0.8M NaCl LB broth. Error bars indicate 
range of maximum and minimum values. 
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Figure S1. Distribution of IncHI1 loci among S. Typhi isolates. X-axis indicates 
the number of IncHI1 plasmid loci (out of 231 targets) generating a fluorescent signal 
in the Illumina GoldenGate assay. Isolates clearly fall into two groups: either >90% of 
IncHI1 target loci were detected, indicating presence of an IncHI1 plasmid (red) or 
<10% of IncHI1 target loci were detected, indicating absence of any IncHI1 plasmid 
(blue). 
 
 
Supplementary Information 
Table S1 – Bacterial isolates analysed in this study 
Table S2 – IncHI1 SNP loci targeted in this study 
Table S3 – Phenotype array results 
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